Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 5:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,020 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Coagulation Disorders Clear all
Completed No phase listed Observational Accepts healthy volunteers

Effect of DT56a (Femarelle) on the Coagulation System in the Treatment of Postmenopausal Women

NCT00883272
View directory record Official record
Conditions
Menopause, Thrombophilia
Interventions
DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel]
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Jul 24, 2026, 5:49 AM EDT
Recruiting No phase listed Observational

The CoAGulation Biomarkers and Atrial Fibrillation (COAG-AF) Pilot Study

NCT04947657
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 24, 2026, 5:49 AM EDT
Withdrawn Not applicable Interventional

FFP Versus PCC in Intracranial Hemorrhage

NCT02429453
View directory record Official record
Conditions
Intracranial Hemorrhage, Traumatic, Intracranial Hemorrhage, Spontaneous
Interventions
Four Factor Prothrombin Complex Concentrate, Fresh Frozen Plasma
Drug · Biological
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Jul 24, 2026, 5:49 AM EDT
Completed Not applicable Interventional Results available

The Utility of Peri-operative Arnica Montana for Reduction of Ecchymosis in Rhinoplasty Surgery

NCT01164644
View directory record Official record
Conditions
Ecchymosis
Interventions
Arnica montana, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Jul 24, 2026, 5:49 AM EDT
Terminated Phase 3 Interventional Results available

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A

NCT01434511
View directory record Official record
Conditions
Hemophilia A
Interventions
OBI-1
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
6 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Jul 24, 2026, 5:49 AM EDT
Recruiting No phase listed Observational

Vasculitis Pregnancy Registry

NCT02593565
View directory record Official record
Conditions
Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Granulomatosis With Polyangiitis (GPA), Wegener's Granulomatosis, IgA Vasculitis, Henoch-Schoenlein Purpura (HSP), Microscopic Polyangiitis (MPA), Polyarteritis Nodosa (PAN), Takayasu Arteritis (TAK), Urticarial Vasculitis, Systemic Vasculitis
Interventions
Online questionnaires
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 24, 2026, 5:49 AM EDT
Completed No phase listed Observational

Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study

NCT01862367
View directory record Official record
Conditions
Congenital Bleeding Disorder, Congenital FXIII Deficiency
Interventions
catridecacog
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
7
States / cities
Orange, California • Tampa, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Jul 24, 2026, 5:49 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

NCT06754852
View directory record Official record
Conditions
Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Interventions
HMB-002 (Part A), HMB-002 (Part B), HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US)
Drug
Lead sponsor
Hemab ApS
Industry
Eligibility
16 Years to 69 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 24, 2026, 5:49 AM EDT
Recruiting No phase listed Observational

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

NCT06008938
View directory record Official record
Conditions
Hemophilia B
Interventions
HEMGENIX, Factor IX (FIX)
Genetic · Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2043
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jul 24, 2026, 5:49 AM EDT
Terminated Phase 3 Interventional Results available

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding

NCT00184548
View directory record Official record
Conditions
Acquired Bleeding Disorder, Trauma
Interventions
eptacog alfa (activated), placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 70 Years
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Jul 24, 2026, 5:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.

NCT01933035
View directory record Official record
Conditions
Immune Thrombocytopenia, Chemotherapy Induced Thrombocytopenia, Myelodysplasia, Aplastic Anaemia
Interventions
Immune Thrombocytopenics, Hypo-proliferative thrombocytopenics, Control Population
Other
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Jul 24, 2026, 5:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)

NCT03205163
View directory record Official record
Conditions
Hemophilia A
Interventions
Advate (Low Dose), Advate (High Dose), BIVV001 (Low Dose), BIVV001 (High Dose)
Biological
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Jul 24, 2026, 5:49 AM EDT
Completed Phase 2 Interventional

Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer

NCT00002504
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
aldesleukin, recombinant interferon alfa
Biological
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1999
U.S. locations
5
States / cities
Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 11, 2011 · Synced Jul 24, 2026, 5:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Post-resection Treatment of Large Colon Polyps

NCT03654209
View directory record Official record
Conditions
Recurrence
Interventions
Argon Plasma Coagulation, Snare Tip Soft Coagulation
Device
Lead sponsor
Indiana University
Other
Eligibility
25 Years and older
Enrollment
384 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Orlando, Florida • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Jul 24, 2026, 5:49 AM EDT
Completed Phase 2 Interventional

Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII

NCT00245245
View directory record Official record
Conditions
Hemophilia A
Interventions
recombinant porcine coagulation factor VIII (OBI-1)
Drug
Lead sponsor
Octagen Corporation
Industry
Eligibility
12 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Blue Bell, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2007 · Synced Jul 24, 2026, 5:49 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

NCT05653219
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Ianalumab, Eltrombopag, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Yuma, Arizona • Aurora, Colorado • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 24, 2026, 5:49 AM EDT
Terminated Phase 3 Interventional Results available

Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A

NCT01405742
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
rF.VIII
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Jul 24, 2026, 5:49 AM EDT
Completed No phase listed Observational

Transfusion Using Stored Whole Blood

NCT02926274
View directory record Official record
Conditions
Trauma, Hemorrhage, Coagulopathy
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Jul 24, 2026, 5:49 AM EDT
Completed No phase listed Observational

A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia

NCT03660774
View directory record Official record
Conditions
Haemophilia A, Haemophilia B
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
1 Year to 21 Years · Male only
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
22
States / cities
Los Angeles, California • Orange, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Jul 24, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Results available

Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies

NCT03103542
View directory record Official record
Conditions
Hemophilia A
Interventions
Recombinant coagulation factor (rFVIIIFc)
Biological
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 24, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT00441090
View directory record Official record
Conditions
Chronic Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic
Interventions
Placebo, Avatrombopag tablets
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
25
States / cities
Anaheim, California • Bakersfield, California • Concord, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Jul 24, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Results available

ECMO Hemostatic Transfusions in Children

NCT05796557
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation Complication, Hemorrhage, Thromboembolism, Transfusion Adverse Reaction
Interventions
Platelet Transfusion
Biological
Lead sponsor
Yale University
Other
Eligibility
Up to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
Atlanta, Georgia • Iowa City, Iowa • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Jul 24, 2026, 5:49 AM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT06034002
View directory record Official record
Conditions
Myeloproliferative Neoplasms
Interventions
INCA033989, Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
Duarte, California • Palo Alto, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 24, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia

NCT00066430
View directory record Official record
Conditions
Anal Cancer, Precancerous Condition
Interventions
infrared photocoagulation therapy, Infrared Coagulator
Procedure · Device
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Jul 24, 2026, 5:49 AM EDT